8 - 9 September 2021
9th Annual Biologics World Taiwan 2021
Virtual Conference
Join the 9th Annual Biologics World Taiwan 2021!
200+
High Profile Attendees
30+
Industry Experts & Speakers
20+
Hours of Networking
10+
Case Studies
The Concept
While China, India, and Korea are leading the pack in the Asian region for biologics, Taiwan has also been stepping up its efforts to boost its biologics sector and capture a share of the global market. The 2009 national plan for biotech development helped kick-start the sector, which has since doubled in revenue size to reach NT$ 118.6bn (US$3.8bn) in 2019. The main focus is on the development of new drugs and biologics.
Strong government commitment has helped drive the expansion of the biotechnology sector. Two biotechnology clusters have already been built in Taiwan and the official opening of the National Biotechnology Research Park (NBRP) in Taipei City's Nangang District in 2018, marked an important milestone for the biomedical industry, as it will integrate Taiwan's R&D and start-up incubation capabilities, focusing all the pre-clinical trial activity in a single location.
Biologics World Taiwan provides the FIRST and ONLY platform for senior decision-makers who will influence the future of Taiwan’s biologics industry. Taiwanese and international biopharmas, biotechs, CMOs, CROs, and solution providers will convene to discuss strategic issues, leverage partnerships, share best practices, and capitalize on the potential of Taiwan’s growing biologics industry.
Conference Agenda
Into its 9th edition, Biologics World Taiwan has firmly established itself as Taiwan’s THE biopharmaceutical gathering for new partnerships, ideas, and knowledge. It has doubled its attendee numbers year after year, with 100% of participants judging the conference to be an excellent and beneficial experience. We are proud to continue providing the meeting platform where Taiwan’s growing biopharma industry is at the central stage, receiving more and more global attention on its fast advancement in new biologic drug R&D and biomanufacturing. If you think of these interests, you know more by downloading the brochure!
Registration
2020 Speakers
HunChi Lin Libo Pharma Corp
Former CEOLibo Pharma CorpTaiwan
Rita Yen-Hua Huang Center for Cell Therapy and Reneration Medicine
CEOCenter for Cell Therapy and Reneration MedicineTaiwanDr. Rita YH Huang currently is the Distinguished Professor and Dean of the Office of Research and Development, Taipei Medical University, and the CEO/Director of TMU Research Center for Cell Therapy and Regeneration Medicine (TMU CCTRM)/TMU GTP Laboratory. Her research interests are on the stem cell translational medicine, from the bench to the bedside. Dr. Huang has an established outstanding track record in the fields of stem cell biology, pathology, and cell therapy. She has devoted herself for more than 20 years in studying the niche regulation of embryonic pluripotency, cancer stemness/drug resistance, and the development of systemic safety cell therapy products. She has published many high impact works in top-ranking journals such as Cancer Research, Clinical Cancer Research, American Journal Gastroenterology, and Stem Cell Reports, and has owned two stem cell patents. As a CEO/Director of CCTRM/GTP Lab at TMU, Dr. Huang leads the TMU cell therapy research/clinical trial teams to execute cell therapy clinical trials using systemic safety stem cells targeting ageing-related unmet needs such as diabetes foot ulcer and cancers.
Dr. Huang has been awarded the 2016 Outstanding Basic Research Award for Cancer Medicine of Dr. Da-Cheng Tung, The Chinese Oncology Society (COS), Taiwan, and twice received the TMU Excellence in Research, Teaching, and Administration Award in both 2013 and 2018, the Excellent Teaching Award of Ministry of Education, ROC in 2019, and the National Innovation Award, Taiwan in 2019. She has also twice been awarded the MOST Outstanding Young Scientist Research Grant (2012-2015 and 2015-2018). Dr. Huang now is the chief principle investigator of two program projects on “Regeneration Medicine Technology Development” (2017-2020) and “Sorafenib-Resistance Hepatocellular Carcinoma” (2018-2021) for the Ministry of Science and Technology (MOST) Executive Yuan, Taiwan. Dr. Huang honored to be invited as the MOST Reexamination Committee Board (2016-2019), and the MOEA Project Review Board (2019-), and the International Project Review Board of Food and Health Bureau (FHB) of The Government of the HKSAR, Hong Kong (2015-2019).
Dr. Ko-Chung Lin PharmaEssentia Corp.
CEOPharmaEssentia Corp.TaiwanDr. Ko-Chung Lin, CEO of PharmaEssentia Corp., is an accomplished scientist with more than 25 years of experience in drug discovery and development. He received his Ph.D. from the University of Missouri, followed by postdoctoral research at the University of Michigan. His work at Monsanto-Searle on HIV protease inhibitor project resulted in an AIDS drug on the market. Dr. Lin was also the co-founder of the discovery chemistry team at Biogen, where he led the team to discover their first drug candidate that was later licensed to Merck. In addition, he is also the holder of more than 40 patents. Under Dr. Lin’s leadership, PharmaEssentia Corp. has successfully developed its flagship product, ropeginterferon alfa-2b, a novel mono-pegylated interferon with improved pharmacological properties.
Lee Cheng Liu Eirgenix
President & CEOEirgenixTaiwanDr. Liu has 30 years of product, process development and manufacturing experience in biotech, pharmaceutical and specialty chemical industries. Prior to returning to Taiwan to start up EirGenix, Dr. Liu was the President and COO of AnGes Inc., a biotech enterprise in its late developmental stage.
He joined AnGes in 2002 as a Vice President of Product Management. He also served as a Vice Chairman in the Supervisory Board of Avontec GmbH, a Munich based joint venture with AnGes, from 2004 to 2010.
Before his tenure with AnGes, he had served various management and professional positions to lead product/process development at GenVec, Novartis, W.R.Grace & Co. and Halcon SD.
Mahalia Corrales JHL Biotech
Senior Director of Process DevelopmentJHL BiotechTaiwanMahalia joined JHL Biotech in May 2018. In JHL Biotech, she oversees the drug substance process development and clinical manufacturing of biologics products. She is an accomplished leader in biologics drug substance development and manufacturing with over 20 years serving in various leadership roles in Process Development, Manufacturing Sciences and Technology, Engineering, and Drug Substance Commercial Manufacturing with Biogen Idec and Genentech. Mahalia has a B.S. degree in Chemical Engineering from University of CA, Los Angeles.
Shuichi Yamamoto Yamaguchi University
DirectorYamaguchi UniversityJapanHe received a BS degree in 1976, a MS in 1978 and a Ph. D in 1981 in the department of Food Science and technology at Kyoto University. He has been at Yamaguchi University since 1981 (Assistant Professor 1981-1988, Associate Professor 1989-1997, Professor 1998-present).
He teaches basic chemical engineering, biochemical engineering, separation engineering, transport phenomena, computer calculations for chemical engineering and process design.
His research interests are in the field of biochemical engineering, food engineering and mass transfer.
He received a 2004 research excellence award from the Society of Chemical Engineers Japan on “Engineering analysis of chromatography of proteins” and a 2005 research excellence award from Japan Society for Food Engineering on “Drying of liquid foods and inactivation of enzymes during drying”.
The following paper has been recognized in the “Top-75 most cited articles” as published in the IChemE journals 2006 – 2009. Shuichi Yamamoto and Ayako Kita, Rational design calculation method for stepwise elution chromatography of proteins, Trans.IChemE.Part C., Food and Bioproducts Processsing, Vol.84, C1, 72-77,2006
He has published more than 100 scientific papers. Among them, his monograph published in 1988 by Marcel Dekker “Ion-Exchange Chromatography of Proteins” is well-known. His chromatography model better known as “Yamamoto Model” and “Yamamoto number” has been employed by various biotech companies as well as by academic researchers. It is partly explained in Perry’s Chemical Engineering Handbook (pp.16-44, 16-45). A text book “Bioseparations Science and Engineering” by R.G.Harris et al. (Oxford press, 2003) describes in detail how to use his model with a Yamamoto number. His diffusion-based drying model is also called “Yamamoto model” as well, and has been used by many researchers.
He is a sub project leader of the National research project (Manufacturing Technology Association of Biologics).
He has also published several text books (chapters) for drying, mass transfer and adsorptions. He has been organizing a course “Basic Chemical Engineering“, for those who are working at chemical industries.
Currently he is Vice President of Asian Pacific Confederation of Chemical Engineers (APCChE) and a board member of World Chemical Engineering Council (WCEC) as a representative of the Society of Chemical Engineers, Japan (SCEJ).
He also serves as an editorial board member for the following journals; Separation Science and Technology, Preparative Biochemistry and Biotechnology, BioProcess International, Japan Journal of Food Engineering (Chief Editor).
For his university, he serves as the vice director of the university library and the director of Biomedical Engineering Center (YUBEC).
Jan-Mou Lee Full Hope Biomedical Co., Ltd.
Jan-Mou LeeFull Hope Biomedical Co., Ltd.Taiwan
Jason Huang BRIM Biotechnology
CEO & CMOBRIM BiotechnologyTaiwan
James C. Tsai UnicoCell
General ManagerUnicoCellTaiwan
Pauline Y. Lau Suntec Medical
CEOSuntec Medical TaiwanDr. Lau is founder and CEO of Suntec Medical, Inc. Suntec Medical markets its products actively in pharmaceutical emerging countries and focuses on biopharmaceutical businesses. It is now trading in 40+ countries covering Latin America, Russia/CIS, and MENA (Middle East and North Africa) countries.
Prior to Suntec, Dr. Lau worked at Hoffman la Roche, Switzerland for over 20 years taking various positions including Senior Director of Integrated Medicine, Directors of Scientific Marketing, Customer Service, and Director of R/D. The scope of her technical expertise includes translational medicine, pharmaceutical clinical development, biomarker development for the clinical trial, and diagnostic product development. Dr. Lau established the projects of three famous drugs in late-stage clinical trials: Rituxin (Anti-CD20), Herceptin (Anti-HER2), and Pegasys (Pegylated IFN-α2a), and participated in early diagnostic development in 5 diseases areas: inflammation (Rheumatoid arthritis), infectious diseases (HIV, HPV, HCV), neuropathic pain, oncology, and urology.
Dr. Lau is on the advisory board and consultants to major medical businesses including APEX pharmaceuticals (USA), and Industrial Technology Research Institute (Taiwan). She is also visiting faculty appointed by the College of Medicine, National Taiwan University.
Dr. Wan-Jiun Chen Oneness Biotech
Deputy Director in Department of Therapeutic AntibodyOneness BiotechTaiwanDr. Wan-Jiun Chen, currently work in a Research& Development biopharma Oneness Biotech and function as a deputy director in Department of Therapeutic Antibody. After graduated from NTU, the developed cancer stem cell drug screening platform and Anti-CSC therapeutic had been licensing to Fountain Biopharma. She had join Fountain Biopharma in 2017 and set up the cancer stem cell drug screening platform and continue developed the Anti-CSC therapeutics. Since the Fountain Biopharma had been merged by Oneness biotech in 2019, she join Oneness Biotech and have the industrial, academic, and GCLP experience in new drug R&D, translational study, hypothesis development, experimental design, biomarker strategy. Experienced people and project manager involved in international and domestic collaborations with internal cross-function teams, academic partners, vendors, and CROs.
William Hung Maria Von Stem Cell and Biotechnology
PhysicianMaria Von Stem Cell and BiotechnologyTaiwanDr. William Hung is currently the CMO and Assisting Physician at Maria Von Stem Cell and Biotechnology in Taiwan. He also worked for the company as a Consultant in Clinical Research and Development. He obtained his education from the College of Medicine at the Taipei Medical University.
Dr. Shue-Yuan Wang The Development Center for Biotechnology
ConsultantThe Development Center for BiotechnologyTaiwanDr. Shue-Yuan Wang currently works as a consultant for DCB (The Development Center for Biotechnology) and a few biotech companies in Taiwan. Upon returning from the USA in 2013, she worked at PharmaEssentia Corp. for a couple of years as Senior Director responsible for the BioProcess Engineering group and the GMP Production Plant. Dr. Wang started her biopharma career in 1986 and has been in the industry for more than 30 years. She worked at Roche, Johnson and Johnson, Amgen, Abbott, Human Genome Sciences, Life Technologies, and Dendreon; with managerial experience up to the Senior Director level. She was involved in and responsible for production process development, scale-up, manufacturing support, and/or regulatory submission for many biologics drugs; such as EPO, Aranesp, Prolia, Humira, Benlysta, ABthrax, Albuferon, Provenge, etc.
Julio Lin Blue Blood Biotech Corp
Vice PresidentBlue Blood Biotech CorpTaiwanDr. Lin is a biomedical scientist with over 20 years of commercial process in life science industries, including medical devices, pharmaceutical, biomaterials manipulate technology and biochips.
Prior to joining Blue Blood Biotech Corp., Dr. Lin was the Deputy Project Director of Industrial Technology Research Institute (ITRI), which is a biggest R&D organization in Taiwan engaging in applied research and technical services.
He was responsible for global cooperation in integrates from small to big key account’s company to form a complete strategic alliance. He was Senior VP at Body Organ Biomedical Inc (listed company in Taiwan Stock Exchange Market) with cross continental’s office, covering TWN, China and the Netherlands.
During his around 10 years tenure at BOBC, which proceeded rapidly co-built sales organization operation at the Netherlands including related regulation approval.
He was not only build efficiency way to synergistic clinical trials and marketing tools, but also broadens the sales channels by shifting the company’s focus from ophthalmology oriented to biomaterials.
As a headquarter based in Taiwan, he lead the team to get first grant of SenterNovem from Ministry of Economic Affairs of the Netherlands for 0.3 million Euro with leading multinational research teams of China, Taiwan and the Netherlands in 2009!
He had successfully filing 36 patents with cost effective strategy of joint research in ProTop Mediking Biomedical Inc. In 2000, he initiated and ready for registration of class II medical device in Purzer pharmaceutical company, this is the first bone filler registration in Taiwan.
Dr. Lin was not only earned his Ph.D. from the Institute of Bioengineering in National Taiwan University but also expand his training to business by get a MBA degree from National Chen Chi University.
Dr. Leah Lo Orient Pharma
CEOOrient PharmaTaiwanDr. Leah Lo has extensive experience in strategic management of intellectual property in the biotechnology area. Her experience includes the consultation both domestic and foreign patent applications and the negotiation of license or collaboration agreements. Currently, she is the President of Medical and Pharmaceutical Industry Technology and Development Center (PITDC), Member of Intellectual Property Rights Committee, Council of Agriculture, Executive Yuan; Member of Intellectual Property Protection Committee, Chinese National Federation of Industries. She is an experienced invited speaker in intellectual property and technology transfer fields among various universities, associations and international conferences. She is adjunct Professor at National Taiwan Ocean University.
Prior to joining Orient Pharma Inc., Dr. Leah Lo had served as President of Medical and Pharmaceutical Industry Technology and Development Center (PITDC), Director of Open Innovation Center, Ministry of Economic Affairs; Director of Technology Transfer Office, National Health Research Institutes (NHRI); Deputy Director of Planning and Evaluation Office, Institute for Information Industry; Deputy Director of Science and Technology Law Center, Institute for Information Industry; Manager of Legal Affairs, Office of Planning and Industrial Service, Development Center for Biotechnology; Manager of Technology Transfer and International Affairs, Development Center for Biotechnology.
Shih-Hwa Chiou Taipei Veterans General Hospital
Director, Department of Medical ResearchTaipei Veterans General HospitalTaiwanShih-Hwa Chiou is Director, Department of Medical Research, Taipei Veterans General Hospital, Taiwan. He is also a Distinguished Chair Professor, The Institute of Pharmacology / The Institute of Clinical Medicine & Gemonic Center, National Yang-Ming University, Taiwan and Appointment Researcher, Genomics Research Center, Academia Sinica, Taiwan.
Dr Chiou was a visiting scholar in Stem Cell Center, Harvard Medical School, Boston Children Hospital, MA, USA, Visiting Researcher in Department of Molecular Biochemistry, The Scripps Research Institute, USA, and Post Doc from Bone Marrow Transplant Center, USA, PhD and MD from National Yang Ming University
He has published 210 papers focusing on stem cell, gene delivery, cell therapy and medicine research.
From year 1995 till now, he has delivered 15 speeches at medical sciences conference in Taiwan and internationally and 75 speeches being delivered for biotechnology symposiums domestically and internationally.
Eric C.C. Tang Lukas Biomed Inc.
Chairman and General ManagerLukas Biomed Inc.TaiwanDr. Eric Tang completed his first degree in Business Administration at Carnegie Mellon University, Tepper School of Business. He then attended the School of Medicine and further pursued his postgraduate education at the Institute of Brain Science in National Yang Ming University (NYMU), then returning to basic science research as he realized many unanswered questions in our current knowledge on cancer today.
Dr. Tang joined Galilee Biotech Inc. in 2012, then was appointed as the Chairman of the company in 2015. In the same year, he was also appointed as the General Manager of Lukas Biomedical Inc. He visited Lymphotec Inc. in Japan and served as a researcher in onco-immunology, then completed the training in Japan and successfully transferred the patented technology of Lymphotec to Lukas Biomed Taiwan. After that, he has devoted himself wholeheartedly in the research and development of “Adoptive T Cell Therapy”. Lukas Biomed began its collaboration with Taipei Veterans General Hospital in 2014 and initiated the first T cell clinical trial in combination with chemoradiotherapy for head and neck cancer in Taiwan. In addition, Lukas Biomed managed to obtain Orphan Drug Designation for their T cell products in the use of HCC in US and pre-IND approval was given in 2018. Dr. Tang merged Galilee Biotech and Lukas Biomed in 2018 as part of the new business and research strategy. The new company’s board appointed him as the new Chairman and General Manager of the company to develop a holistic care model for cancer patients. At present, Lukas Biomed Inc. is not only a leading pioneer in T cell immunotherapy research but also the second largest home nursing brand in Taiwan.
Stanley SC Chang Medigen Biotechnology Copr
CEO/ChairmanMedigen Biotechnology CoprTaiwanStanley SC Chang is Chairman and CEO, Medigen Biotechnology Corp, Taiwan.
Dr Chang has a Ph.D in National Medical Laser Centre, University College London, UK and MD, School of Medicine, National Taiwan University.
Prior to joining Medigen Biotechnology Corp, he was the chairman for Winston Pharmaceutical Company and Director for TBG Molecular Diagnostic LTD Australia.
He has published 44 scholastic speeches delivered at International Medical Science Conference and 54 peer reviewed papers, 30 of them are SCI Papers, 17 academic and scholastic awards received from a domestic and international organization, associations and foundations.
From year 1995 till now, he has delivered 15 speeches at medical sciences conference in Taiwan and internationally and 75 speeches being delivered for biotechnology symposiums domestically and internationally.
Prof. Liu Hwa-Chang Taiwan Adventist Hospital
Attending Surgeon, Department of OrthopaedicsTaiwan Adventist HospitalTaiwanProf. Liu Hwa-Chang is an Attending Surgeon, Department of Orthopaedics in Taiwan Adventist Hospital.
Dr Lee has a PhD, The University of Tokyo, Department of Orthopaedic Surgery and MD, National Taiwan University, School of Medicine.
Prior to joining Taiwan Adventist Hospital, he was a director in Institute of Biomedical Engineering in National Taiwan University and Professor in Department of Orthopaedics, National Taiwan University Hospital.
He has published 31 journal papers focusing on orthopaedics, biomaterials, medical engineering, periodontology and radiology.
Also, he has been received many awards such as recipient of Best Paper Contest, 3rd and 4th place, SICOT in 2008 and 2009. Recipient of the Teaching Material Innovation Award, National Taiwan University, Hospital 1999 & 2005 and more.
Chun-Che Yen Kartigen Biomedical Inc.
a Deputy General Manager Kartigen Biomedical Inc.TaiwanChun-Che Yen is a Deputy General Manager in Kartigen Biomedical Inc., Taiwan. He is also an Adjunct Professor in Chemical Engineering a Biotechnology Department, in National Taipei University of Technology, Taipei.
Dr Lee has a Ph.D in Institute of Basic Medicine, Biochemistry and Molecular Group from Chang Gung University (ROC) and MS degree in Department of Animal Science, reproduction physiology group, University of California, Davis (USA).
Prior to joining Kartigen Biomedical Inc, he was a researcher in the Industrial Technology Research Institute (ITRI) and Legal Metrology Division, Medical and Chemistry Research Laboratory.
His research interests include stem cell biology and bio tissue engineering, stem cells for repairing chondral defects, cancer stem cell, consultation for cell therapy facility, and measuring living cell’s mechanical properties.
TzuHung Lin Industrial Technology Research Institute (ITRI)
Research ScientistIndustrial Technology Research Institute (ITRI)Taiwan
Yuan-Hua Ding Asia Discovery Labs Emerging Science & Innovation (ES&I), Pfizer Worldwide Research, Development and Medical
Vice President and HeadAsia Discovery Labs Emerging Science & Innovation (ES&I), Pfizer Worldwide Research, Development and MedicalChinaDr. Yuan-Hua Ding is VP and Head of Pfizer Asia Discovery Labs (ADL), Emerging Science & Innovation (ES&I) at Pfizer Worldwide Research, Development and Medical (WRDM). He is also a member of the ES&I leadership team. In this capacity, Yuan-Hua builds and leads an entrepreneurial group of experimental scientists and skilled drug hunters to collaborate broadly with Asia Pacific biomedical R&D communities with the goal of translating promising science into clinical candidates. Yuan-Hua also manages WRDM’s Asia Innovation Fund (AIF) which provides flexible funding to academic collaborations, biotech alliances and NewCo seeding with partners in the Asia Pacific region.
Prior to his current job, Dr. Ding served a variety of roles in the Pfizer R&D division, including Head of External Science and Innovation - Asia Pacific, Head of Structural Biology at the Research Technology Center (RTC) in Cambridge, MA, Associate Research Fellow and Senior Research Scientist. As the Head of the RTC Structural Biology, he oversaw a group of scientists responsible for protein production, characterization, crystallization, crystallography and structure-based drug design. His group supported structural based drug design portfolio of 10+ programs, through collaborative efforts with RTC, Pfizer global structural biology groups and therapeutic area project teams, covering oncology, diabetes, inflammation and CNS. He also served as project leaders for several drug discovery programs with some into the clinics.
Dr. Ding received a bachelor’s degree in Electronic Engineering from Peking University in 1987 and a master’s degree in Biophysics from Tsinghua University in 1990. In 1996, after completion of doctoral studies in Biochemistry with Prof. John Rosenberg and Prof. Roger Hendrix at the University of Pittsburgh, he moved to Harvard University to become a postdoctoral fellow with Prof. Don Wiley. Dr. Ding’s postdoctoral work focused on structural and biophysical aspects of molecular interactions among T-cell receptor (TCR), major histocompatibility complex (MHC) and peptide antigens. While in Prof. Wiley’s Lab, Dr. Ding also collaborated with Prof. Judah Folkman of Boston Children’s Hospital on structural studies of endostatin, a protein shown to be a potent angiogenesis inhibitor in a mouse model.
Hsiu-Ling Hsiao Ever Supreme
Chief Scientific Officer Ever Supreme Taiwan
Yi Pei Hung Yupro Biomedical Services
General Manager Yupro Biomedical ServicesTaiwan
Dr Po Cheng Lin GWOXI
General Manager GWOXI TaiwanDr. Hun-Chi Lin is the CEO of LiBo Pharma Corp. (LiBo), Chairman and President of Global TransBiotech, Inc. (GTB), and Chairman of LifeCode, Inc. He was the Director of Clinical Trials Division at Specialty Laboratories (NYSE: SP; www.specialtylabs.com) where he created and managed the Clinical Trials Division. Under his management, the Clinical Trial Division provided services to support about 400 clinical studies including drugs, biologics, and medical devices. Prior to becoming the Director of Clinical Trials, Dr. Lin managed the Research Lab of Specialty Laboratories. Tests developed under his direction contributed more than 40% revenues of Specialty Laboratories. In addition, he supervised and managed over 100 research collaborations with scientists from academic institutes within the U.S. and abroad. Prior to joining Specialty Laboratories, he co-developed Trigen, Inc. a company focused on the treatment of type-1 diabetes. He has over 30 peer-reviewed publications, five US patents, and many presentations in professional conferences. Dr. Lin graduated from UCLA and holds a Ph.D. degree in Microbiology. He graduated from National Taiwan University and holds a Master degree in Food Science and Technology and a B.S. degree in Agricultural Chemistry.
Dar-Jen Hsieh ACRO Biomedical Co. Ltd.
CEO ACRO Biomedical Co. Ltd.TaiwanDr. Dar-Jen Hsieh founded ACRO Biomedical Co., Ltd. in June 2014. The company is in the leading position of the field of collagen derived medical devices that expertise in tissue engineering and regenerative medicine of human tissues and organs.
Dr. Hsieh received his Ph.D in Cell and Molecular Biology from the State University of New York at Buffalo. He has years of experience in the biotechnology and healthcare field, and has held industrial, governmental, and academic positions.
Dr Ye-Su Chao GNTbm
Vice President GNTbm TaiwanDr. Ye-Su Chao is the Vice President of GNT Biotech & Medicals Corporation (GNTbm). Before worked at GNTbm in 2014, she was Program Director of several government-funded programs, and Director of Department of Technology Transfer, at Bio-promotion & Business Development Division, Development Center of Biotechnology. Her work experience included promotion of industrial development through action of strategic plans, and providing insights on technology valuation/evaluation, technology forecast and licensing-in/licensing-out. Dr. Chao received her Ph.D. degree in Molecular Biology at the University of Southern California in 1992. She was a postdoctoral fellow at the Howard Hughes Medical Institute of University of California San Francisco from 1993 to1997, working on HIV gene regulation, and at the Plant Gene Expression Center of University of California Berkeley from 1992 to 1993. From1998 to1999, she worked as a research scientist at UCSF, focusing on the breast cancer research.
John (Tsu-An) Hsu National Health Research Institutes
Investigator, Division Biotechnology and Pharmaceutical ResearchNational Health Research InstitutesTaiwan
Dr Allen Chao Tanvex
CEOTanvex TaiwanDr. Allen Chao was a co-founder of Watson Pharmaceuticals, Inc. (now Allergan plc), a specialty pharmaceutical company, serving as Chief Executive Officer from 1985 to September 2007. At the time of his retirement from Watson the company had revenue of approximately $3.0 billion a year and it had three business units: Generic Pharmaceuticals, Branded Pharmaceuticals, and Distribution. While at Watson, Dr. Chao oversaw the company's growth, through internal R&D, licensing and acquisitions of pharmaceutical products and technologies, as well as mergers and acquisition activities.
Dr. Chao is currently the Chief Executive Officer of Tanvex BioPharma, Inc., a Cayman company listed on the Taiwan Stock Exchange. Corporation principally engaged in the research, development and manufacture of biosimilars, and Tanvex operates out of its facilities in the United States and Taiwan.
Alvan Chou Mycenax Biotech
R&D Director Mycenax Biotech TaiwanAlvan has over 13 years of industry experience in biologics development. Prior to joining Mycenax, Alvan served as Senior RD Manager of TheVax Genetics Vaccine Co. Ltd, and Reber Genetics Co. Ltd. Alvan obtained a Ph.D. at National Tsing Hua University Department of life Science.
Juine-Ruey Chen RH Biopharma
Vaccine R&D Director RH BiopharmaTaiwanDr. Chen specializes in human vaccine research and antiviral therapies. He joined the RH Biopharmaceuticals. Inc. in Aug 2018. He has over 10 years of practical, hands-on industry experience on human vaccine and human clinical trials. He was previously the Head of R&D at Adimmune Corporation, where he was responsible for vaccine development and clinical manufacturing of new vaccine candidates for providing the design, methods and operators to produce the vaccines.
His major contributions were to produce the GMP grades of cell-based EV71 Inactivated vaccine using serum free medium with single-used bioreactor and successfully finished the phase II and III clinical trials in Taiwan. (2) His team developed the egg-based inactivated H7N9 Vaccine for Phase II/III clinical trials which has met with the vaccine protection criteria and received the approval in Taiwan. (3) He was a team leader for a $3.5 million US dollar of development effort to convert traditional flu vaccine from egg-based to a cell culture-based production process. Prior to Adimmune Corporation, Dr. Chen was a research scientist in Genomics Research Center (GRC), Academia Sinica (AS) focused on developing universal flu vaccine against influenza. His current work is to lead a team for developing universal flu vaccine that can provide durable protection for all age groups against multiple influenza strains, including those that might cause a pandemic.
Sponsors & Exhibitors
Become A Sponsor!
Be part of the ONLY biologics and biosimilars focused platform in Taiwan!
Your business is much more than just knocking on doors. Your marketing strategy is much more than a leads generator. To generate sales, you need brand credibility and a good leadership position. To create awareness and response, you need a targeted and motivated audience who are leaders in both local and international biologics industries that are capable of putting pen to paper. To generate profits, come and embark on the marketing and business development services of Biologics World Taiwan 2020!
Sales and Marketing Opportunities at Biologics World Taiwan!
Biologics World Taiwan is the ONLY event in Taiwan for senior decision-makers who will influence the future of Taiwan’s biologics industry. Leverage on this year’s best marketing and sales opportunity to access the fastest growing biologics market of the world! Be there and be seen!
Market Intelligence
English 
简体中文 
日本語 
한국어 
繁體中文